DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection

Journal of Infectious Diseases

Volumn 176, Issue 4, 1997, Pages 1035-1040

  Zhang, Dong Ji ^a   Yang, Xi ^a   Berry, Jody ^a   Shen, Caixia ^a   McClarty, Grant ^a   Brunham, Robert C ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE TRIPHOSPHATE; DNA VACCINE; OUTER MEMBRANE PROTEIN; SYNTHETASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROVOCATION TEST; VACCINATION;

EID: 0030747201     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516545     Document Type: Article

References (30)

1. Liu MA. Overview of DNA vaccines. Ann NY Acad Sci 1995;772:15-20.
2. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 1995;3:165-9.
3. McDonnell WM, Askari FK. Molecular medicine: DNA vaccines. N Engl J Med 1996;334:42-5.
4. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Ann Rev Immunol 1997;15:617-48.
5. Lowrie DB, Tascon RE, Colston MJ, Suva CL. Towards a DNA vaccine against tuberculosis. Vaccine 1994;12:1537-40.
6. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994;91:9866-70.
7. Xu D, Liew FY. Genetic vaccination against leishmaniasis. Vaccine 1994; 12:1534-6.
8. Barry MA, Lai WC, Johnston SA. Protection against mycoplasma infection using expression-library immunization. Nature 1995;377:632-5.
9. Brunham RC. Vaccine design for the prevention of Chlamydia trachomatis infection. In: Orfila J, Byrne GI, Chernesky JT, et al., eds. Chlamydial infections: Proceedings of the Eighth International Symposium on Human Chlamydial Infections (Chantilly, France). Italy: Societé Aditrice Esculapio, 1994:73-82.
10. Moulder JW. Interaction of chlamydiae and host cells in vitro. Microbiol Rev 1991;55:143-90.
11. Yang X, Brunham RC. T-lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development. Can J Infect Dis (in press).
12. Morrison RP, Manning DS, Caldwell HD. Immunology of Chlamydia trachomatis infections: immunoprotective and immunopathogenetic responses. In: Quin TC, ed. Advances in host defence mechanisms. Sexually transmitted diseases. Vol 8. New York: Raven Press, 1992:52-84.
13. Grayston JT, Wang SP. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis 1978;5:73-7.
14. Grayston JT, Wang SP. New knowledge of chlamydiae and the diseases they cause. J Infect Dis 1975;132:87-105.
15. Taylor HR, Whittum-Hudson J, Schachter J, Caldwell HD, Prendergast RA. Oral immunization with chlamydial major outer membrane protein (MOMP). Invest Ophthalmol Vis Sci 1988;29:1847-53.
16. Tan TW, Herring AJ, Anderson IE, Jones GE. Protection of sheep against Chlamydia psittaci infection with a subcellular vaccine containing the major outer membrane protein. Infect Immun 1990;58:3101-8.
17. Batteiger BE, Rank RG, Bavoil PM, Soderberg LSF. Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. J Gen Microbiol 1993;139:2965-72.
18. Campos M, Pal S, O'Brien TP, Taylor HR, Prendergast RA, Whittum-Hudson JA. A chlamydial major outer membrane protein extract as a trachoma vaccine candidate. Invest Ophthalmol Vis Sci 1995;36: 1477-91.
19. Tuffrey M, Alexander F, Conlan W, Woods C, Ward M. Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein. J Gen Microbiol 1992;138:1707-15.
20. Su H, Parnell M, Caldwell HD. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Vaccine 1995;13:1023-32.
21. Zhong G, Toth I, Reid R, Brunham RC. Immunogenicity evaluation of lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis. J Immunol 1993;151:3728-36.
22. Fynan EF, Webster RG, Fuller DH, Haynes JR, Stantoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-82.
23. Tipples G, McClarty G. Cloning and expression of the Chlamydia trachomatis gene for CTP synthetase. J Biol Chem 1995;270:7908-14.
24. Zhang YX, Fox JG, Ho Y, Zhang L, Stills HF, Smith TF. Comparison of the major outer-membrane protein (MOMP) gene of mouse pneumonitis (MoPn) and hamster SFPD strains of Chlamydia trachomatis with other Chlamydia strains. Mol Biol Evol 1993;10:1327-42.
25. Brunham R, Yang C, Maclean I, Kimani J, Maitha G, Plummer F. Chlamydia trachomatis from individuals in a sexually transmitted disease core group exhibit frequent sequence variation in the major outer membrane protein (omp 1) gene. J Clin Invest 1994;94:458-63.
26. Yang X, HayGlass KT, Brunham RC. Genetically determined differences in IL-10 and IFN-γ responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J Immunol 1996;156:4338-44.
27. Su H, Caldwell HD. Kinetics of chlamydial antigen processing and presentation to T cells by paraformaldehyde-fixed murine bone marrow-derived macrophages. Infect Immun 1995;63:946-53.
28. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995;2:129-35.
29. Zhang DJ, Yang X, Shen CX, Berry J, McClarty G, Brunham RC. Intramuscular immunization with a DNA vaccine produces partial immunity to Chlamydia trachomatis infection. In: Brown F, Burton D, Doherty P, Mekalanos J, Norrby E, eds. Vaccines 97. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1997:113-7.
30. Brunham RC, Kimani J, Bwayo J, et al. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J Infect Dis 1996;173:950-6.